IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH trimmed its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 40.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,387 shares of the company’s stock after selling 937 shares during the quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH’s holdings in IDEXX Laboratories were worth $749,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Valley National Advisers Inc. grew its holdings in IDEXX Laboratories by 84.6% in the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock worth $26,000 after buying an additional 22 shares in the last quarter. Riverview Trust Co bought a new position in IDEXX Laboratories in the 1st quarter worth approximately $26,000. Geo Capital Gestora de Recursos Ltd bought a new position in IDEXX Laboratories in the 3rd quarter worth approximately $28,000. DSM Capital Partners LLC bought a new position in IDEXX Laboratories in the 4th quarter worth approximately $33,000. Finally, Venturi Wealth Management LLC boosted its stake in IDEXX Laboratories by 226.3% during the 4th quarter. Venturi Wealth Management LLC now owns 62 shares of the company’s stock valued at $34,000 after purchasing an additional 43 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have issued reports on IDXX shares. Morgan Stanley decreased their price target on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a research note on Tuesday, May 14th. Stifel Nicolaus decreased their price target on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research note on Monday, June 24th. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Barclays decreased their price target on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. Finally, StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, June 14th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus price target of $586.63.

Insider Activity

In other news, Director Bruce L. Claflin sold 200 shares of the firm’s stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $540.80, for a total value of $108,160.00. Following the sale, the director now directly owns 161 shares of the company’s stock, valued at $87,068.80. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 2.18% of the stock is currently owned by company insiders.

IDEXX Laboratories Price Performance

IDXX opened at $477.23 on Wednesday. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39. The stock has a fifty day moving average of $501.52 and a 200-day moving average of $526.04. The firm has a market capitalization of $39.41 billion, a P/E ratio of 46.20, a PEG ratio of 3.97 and a beta of 1.32.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.13. The business had revenue of $964.10 million during the quarter, compared to analyst estimates of $965.43 million. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. Equities analysts forecast that IDEXX Laboratories, Inc. will post 11.03 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.